title: Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.
abstract: Treatment of cystic fibrosis lung disease has developed from an understanding of the abnormal airway surface liquid resulting from a lack of function of the cystic fibrosis transmembrane regulator protein. Mucus plugging resulting in infection and inflammation leads to airway wall destruction and bronchiectasis. Inhaled therapies have formed the backbone of treatments. In combination with antibiotics delivered direct to the airway, mucoactive drugs, including mucolytics and hyperosmolar agents, are utilised to improve mucociliary clearance to reduce infection and inflammation. Until recently, airway therapies were delivered as nebulisers, but we have now entered the era of dry powder inhalers for treatment of cystic fibrosis lung disease. The theory and practice of these therapies are discussed in this review.
authors.affiliation: Brighton and Sussex University Hospitals, Brighton, UK.
authors.forename: Katharine
authors.initials: K
authors.lastname: Hurt
authors.forename: Diana
authors.initials: D
authors.lastname: Bilton
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005100:Expectorants / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D009079:Mucociliary Clearance / Q000187:drug effects; D011379:Prognosis; D019141:Respiratory System Agents / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D005100:Expectorants; D019141:Respiratory System Agents